View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
In view of the important priority of developing new drugs for the treatment of cancer and methods for determining carcinogenic risk, interested parties should notify this office in writing not later that January 2, 1998. Respondents will then be provided an additional 30 days for filing of formal proposals.
Organizations must submit a confidential proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
Inquiries regarding scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably one page or less, must be submitted to NCI on or before October 10, 1997. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected.
In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than June 26, 1997 for priority consideration.
CRADA proposals should be received on or before July 30, 1997 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.
In view of the important priority of developing new agents for the treatment of infectious disease and related malignancies, interested parties should notify this office in writing no later than April 28, 1997. Respondents will then be provided an additional 30 days for the filing of formal proposals.
